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Abstract
Background: Strains of Dirofilaria immitis suspected of lack of efficacy (LOE) to macrocyclic
lactone (ML) preventive drugs have been increasingly reported in dogs by practicing
veterinarians since 2005 in the Lower Mississippi Delta region. If proven, and not controlled in
the early stages, the emergence of ML drug resistance threatens to become a widespread problem
in the US that may limit the effectiveness of current preventive drug treatment methods.
Methods: To validate practice reports, a statewide survey of Louisiana veterinarians was done to
define the extent of the problem and identify focal ‘hotspots’ of reported ML LOEs using
Geographic Information Systems (GIS) methods. The present study utilized microfilariae (Mf)
from two canine field cases from different state locations that fit criteria for a high index of
suspicion of LOE against heartworms by ML drugs. Blood containing Mf from the field cases
was used to infect and produce infective larvae (L3) in Aedes aegypti for experimental infection
of two groups of dogs, each of which contained two laboratory dogs, one treated with
prophylactic ivermectin (12 μg/kg) monthly for 6 months, and one untreated control.
Results: Both treated and untreated dogs from Group I and Group II developed patent D. immitis
infections by 218 DPI and 189 DPI, respectively, as evidenced by a positive occult heartworm
antigen test and Mf by the Knott’s test. Mf counts gradually increased post-patency in test and
control dogs. L3 raised from Mf from the treated Group I dog were used to successfully establish
a second generation isolate, confirming heritability of resistance in the face of a monthly
ivermectin challenge dose of 24 μg/kg, given monthly for 3 months.
Conclusions: These experimental infection studies provide in vivo evidence of the existence of
ML drug resistance in dogs infected by D. immitis L3 from suspect field LOE cases in the Lower
Mississippi Delta. Results encourage further work on mechanisms underlying the emergence of
v

ML resistance in D. immitis and development of evidence-based resistance management
strategies for heartworm preventives in order to extend the useful life of current drugs.

vi

Chapter 1. Introduction
In 2005, an evaluation of the efficacy of heartworm preventive products was published by
the Center for Veterinary Medicine, US Food and Drug Administration (FDA) that reported
concerns of an increased number of reports by practicing veterinarians on lack of efficacy (LOE)
of macrocyclic lactone (ML) preventive drugs [1]. Eighteen years after the first monthly ML
drug formulation was approved in 1987, monthly ML drugs had largely replaced daily
diethylcarbamazine, an approved treatment since 1977, to become the dominant means of
preventing heartworms in companion animals in the USA. The first ML LOE reports to the FDA,
beginning in 1998, had grown in number to several hundred in 1999–2000, nearly 1000 in 2000–
2001 and over 1500 in 2002–2003 [1]. It was proposed that either true emerging resistance,
enhanced FDA surveillance records systems or climate-based shifts in mosquito vector
population species may have had a role.
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Chapter 2. Literature Review
In response to this, and anecdotal reports of increasing LOE cases from the veterinary
community in heartworm endemic areas, pharmaceutical firms initiated reimbursement programs
in 2004 to cover costs of treatment of LOE cases if owners and their veterinarians could
document full compliance with recommended preventive treatment practices. Concurrently,
several research efforts were initiated, investigating the spatio-temporal scale and dynamics of
LOE reports [2], potential in vitro indicators of resistance [3,4], possible genetic markers of
resistance via genomic studies [5-10] and in vivo experiments, the gold standard, to establish
confirmed resistant strains from canine field cases in the laboratory [11,12].
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Chapter 3. Establishment of Macrocyclic Lactone Resistant Dirofilaria immitis
Isolates in Experimentally Infected Laboratory Dogs
3.1. Objectives
The objectives of studies reported here are to record results of 1) a 2009 survey to
document the experience of veterinarians in Louisiana on potential emerging ML resistance by
D. immitis, and 2) establishment of ML resistant isolates of D. immitis in experimentally infected
laboratory dogs using L3 raised in Aedes aegypti fed on microfilaremic blood from 2 dogs with a
‘high index of suspicion of resistance’.
3.2. Methods
Objective 1: statewide practitioner survey
In August 2009, a one-page ‘check-off’ questionnaire survey was sent to all Louisiana
veterinarians listed in the Louisiana Veterinary Medical Association (LVMA) database and in
the 2008 billing records of the Louisiana Animal Disease Diagnostic Laboratory (LADDL).
Fifteen survey questions queried whether ML LOE cases had been seen in client dogs, including
year of the first ML LOE case, specific drug used on suspected LOE cases, and the number of
ML LOE cases reported. A total of 855 surveys were sent. Survey data results were entered into
a Microsoft® excel (Microsoft Office, 2007) database and linked to a map of Louisiana within a
geographic information system (GIS) according to the longitude/latitude geographic point
location and Zip Code of each responding veterinarian’s clinic using ArcGIS 9.3 software (ESRI,
Redlands, CA) [2].

---------This chapter was previously published as Pulaski, C.N., Malone, J.B., Bourguinat, C. et al.
Establishment of macrocyclic lactone resistant Dirofilaria immitis isolates in experimentally
infected laboratory dogs. Parasites Vectors 7, 494 (2014).
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Objective 2: experimental infection studies
Field isolates
Microfilariae (Mf) positive blood from canine field cases from different state locations
was collected from client-owned dogs for use in the current study. After review and approval of
experimental protocols by the Louisiana State University Institutional Animal Care and Use
Committee, owner consent forms informing clients of the study purpose and design were agreed
upon and signed prior to enrollment in the study. Based on practitioner and client cooperation,
two dogs were selected based on the following criteria for a ‘high index of suspicion of ML
resistance’ by D. immitis:
a) History of failure of efficacy and full monetary compensation by a commercial
pharmaceutical firm;
b) Residence in an area identified as a ‘hotspot’ of suspected ML drug resistance in the 2009
statewide veterinary practitioner survey of LOE cases [2];
c) Persistence of circulating Mf following an accepted microfilaricidal dose of ML [8] and;
d) High frequency of a genotype marker previously reported to be correlated with potential
ML resistance, single nucleotide polymorphism at sites 11 and 618 (GG-GG) of a gene
encoding for P-glycoprotein [5].
Dogs
Four male hound-cross dogs of 4–5 months-of-age were purchased from a USDA
approved commercial supplier for experimental infections. All dogs were housed strictly in
indoor runs in a mosquito-free kennel facility confirmed by periodic overnight sampling using a
CDC Miniature Light Trap, Model 512 (John W Hock Co., Gainesville, FL). All dogs tested
negative for adult heartworm antigen (DiroCHEK® Canine Heartworm Antigen Test Kit,
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Symbiotics Corporation, San Diego, CA, USA) in serum samples collected prior to experimental
infection and at 1-, 2-, 3-, and 4-months post-infection. None of the dogs were treated with any
ML in the holding period before experimental infection of dogs with D. immitis L3 at 12–15
months-of-age.
Experimental design
Dogs were randomly assigned to two groups of two dogs for experimental infection by
the two field isolates (Group I – “LSU 10” strain; Group II – “LSU 13” strain). At 27–33 days
after infection, one dog in each group was treated with 12 μg/kg ivermectin diluted 1:9 in
propylene glycol by the subcutaneous (SC) route. The untreated control dog received a similar
volume of only propylene glycol by the SC route. At monthly intervals thereafter, dogs received
respective ivermectin (12 μg/kg) or propylene glycol sham treatment for a total of 6 monthly
treatments.
Although not required to confirm resistance, the ivermectin monthly treatment was
repeated six times, at double the recommended dose, in order to ensure the presence of
resistance. Ivermectin drug (Merial, Ivomec® 1% Injection, 50 mL) was from batch number
BA132/10 (certificate of analysis available).
D. immitis infection
Blood containing Mf from the two canine field cases was collected and used to infect
laboratory-raised Aedes aegypti mosquitos using a membrane feeding apparatus (Thermo
NESLAB, Model RTE-111, Neslab Instruments, Newington, NH, USA). Mosquitoes were
infected and held in an insectary for 14–16 days (27°C, 80% RH, 12 hour light cycle) prior to
harvesting L3 according to the procedure of the NIAID/NIH Filariasis Research Reagent
Repository Center (FR3), Athens, GA, USA [13]. Each dog received a SC inoculation in the

5

inguinal area containing infective third-stage D immitis. Recovered L3 were held in RPMI tissue
culture media at room temperature for up to 3 hours until SC inoculation. Group I (LSU 10) dogs
each received 69 L3 (31 on 23rd March 2012 and 38 on 30th March 2012) and Group II (LSU
13) dogs each received 75 L3 (test) or 114 L3 (untreated control) on 15th June 2012. Group I
dogs were infected twice, one week apart, because an adequate number of L3 larvae were not
obtained following the initial harvest. Whole blood samples were collected from each dog at
monthly intervals for four months following experimental infection, and at two week intervals
thereafter, to determine D. immitis infection status and the onset of patency. Blood samples were
analyzed for adult heartworm antigen (Dirochek® Canine Heartworm Antigen Test Kit,
Symbiotics Corporation, San Diego, CA) and the presence of microfilariae was monitored using
a 20 μL direct blood smear and the modified Knott’s technique [14]. Results were recorded over
time as number of days post-infection (DPI).
Heritability
In separate follow-up studies, infective larvae raised from microfilariae from the treated
Group I dog (LSU 10 strain) were used to confirm heritability of resistance in the face of a
monthly ivermectin challenge dose of 24 μg/kg for 3 monthly treatments. Similar procedures to
those previously described were used to infect (45 L3) and monitor the dog used to establish this
second generation isolate of the LSU 10 strain (LSU 10-II). An ivermectin treatment dose at 4
times the recommended preventive level was used to further confirm strain resistance, which had
previously been assessed at twice the recommended level.
Ethical approval
This study was reviewed and approved by the Louisiana State University Institutional
Animal Care and Use Committee (PRN 13–072).
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3.3. Results
Statewide survey
Of the 855 one-page mail surveys sent to all Louisiana practitioners in August 2009
regarding their opinions of ML LOEs reported within their clinics, 221 were returned (25.8%
response rate). Of the 221 surveys submitted, 70% were from clinics classified as ‘small animal’
and 25% were from ‘mixed animal’ facilities. GIS analyses of survey results indicated there were
focal locations with veterinarian perceived high rates of reported LOEs of ML drugs against
heartworms and that numbers increased from 2005 to 2008. Pertinent survey questions with
results are shown in Figure 1 [2].
Experimental infections
Both treated and untreated dogs from Group I (LSU 10) and Group II (LSU 13)
developed patent D. immitis infections by 218 DPI and 189 DPI, respectively, as evidenced by a
positive occult heartworm antigen test and microfilaremia by the modified Knott’s test. Mf
counts gradually increased post-patency in test and control dogs (Table 1)
Heritability of resistance
Microfilaremia in one of the dogs (LSU 10a), initially found in moderate numbers,
became sporadic with biweekly counts of 2–8 Mf per ml of blood. Microfilariae from this dog
(LSU 10a) were used to 1) maintain an adequate Mf lev generation passage of the to a new
laboratory dog (LSU 10-II); 2) to confirm resistance in the face of challenge treatment by a

7

Figure 1. Pertinent Survey Questions with Results
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Table 1. Monthly Parasitological Monitoring
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24 μg/kg dose of ivermectin given monthly for 3 months, and 3) to demonstrate heritability of
the LSU 10 resistant strain. Monthly monitoring of the LSU 10-II dog showed it became positive
for circulating antigen by 204 DPI and became patent with circulating Mf by 259 DPI. Five
laboratory dogs harboring resistant strain D.immitis isolates from two separate client-owned dogs
(LSU 10, LSU 13) are thus currently available for further study:
Dog challenge treatment


LSU 10a ivermectin (12 μg/kg, monthly for 6 months)



LSU 10b untreated control



LSU 10-II ivermectin (24 μg/kg, monthly for 3 months)



LSU 13a ivermectin (12 μg/kg, monthly for 6 months)



LSU 13b untreated control
We propose that we have successfully isolated two strains from proven cases of

resistance in client-owned dogs in Louisiana that can be used to further study and characterize
the emergence of ML resistance by D. immitis.
Genomics studies
Samples of 20–30 individual Mf, from Group I and Group II D. immitis infected dogs,
were collected, preserved in isopropyl alcohol, and analyzed blindly in order to genotype the
circulating Mf population for two single nucleotide polymorphism loci on a P-glycoprotein gene
previously shown to be correlated with a loss of efficacy of macrocyclic lactone heartworm
anthelminthics [5-7]. The investigation of percentage frequencies of GG-GG genotype in the
different groups was the main interest. DNA extraction of individual Mf had been extracted
following the protocol of QIAamp DNA Micro kit from Qiagen® (www.qiagen.com). Also,
individual Mf DNA samples had been amplified using Repli-g screening kit from Qiagen®, to
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increase DNA concentration of individual samples. Individual genotypes had been identified
after PCR, Sanger sequencing, and analysis of chromatograms using Sequencher®
(http://genecodes.com/). Table 2 shows results of preliminary studies on Mf from the original
two client owned dogs (LSU 10, LSU 13) used to establish resistant strains in the laboratory as
compared to Mf from two dogs from a police dog kennel (LSU 11, LSU 14). Results showed a
higher percentage frequency of GG-GG genotype in Mf populations from LSU 10 and LSU 13
strain dogs compared to Mf population from LSU 11 and LSU 14.

Table 2. Genomics Studies

Percentage frequency %
AA-AA

AA-GG

AA-AG

AG-GG

GG-GG

GG-AA

??-GG

??-AA ??-AG

Total

N

LSU10

10.0

13.3

3.3

0.0

40.0

3.3

23.3

3.3

3.3

100.0

30

LSU11

11.1

70.4

3.7

0.0

7.4

0.0

7.4

0.0

0.0

100.0

27

LSU13

0.0

41.4

0.0

6.9

51.7

0.0

0.0

0.0

0.0

100.0

29

LSU14

8.7

60.9

4.4

0.0

17.4

0.0

8.7

0.0

0.0

100.0

2

Note: Preliminary study of PCR analysis of 23–30 individual microfilariae showing high frequency of the GG-GG
marker from dogs harboring proven resistant strains (indicated in bold) as compared to pooled microfilariae from
two infected dogs from a local police dog kennel. Result?? Inconclusive (position 11 undetermined, position 618
determined)
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3.4. Discussion
The aim of the current study was to provide evidence to test the following hypothesis –
‘Resistant strain(s) of D. immitis exist in the general population of Louisiana dogs, and these
resistant strains can be identified by case history, in vivo tests and genetic markers to enable
development of effective alternative drug therapies to extend the useful life of current preventive
drugs’. Beginning in 2005, LOE reimbursement programs by pharmaceutical firms provided an
opportunity to study pre-screened records of possible resistance and made it more likely to
identify sporadic cases of resistance, if present, in the general population of dogs in South
Louisiana. The ‘microfilariae reduction test’ proposed by Geary et al. [8] provided a simple
method for testing potential drug failure that could be used in clinical settings when resistance
was suspected. Initial studies on the ‘Katrina dog’ [5] and other suspect cases [6,7] provided a
potential new tool to find cases based on genetic markers of ML resistance by D immitis. Finally,
a statewide survey was done of Louisiana veterinary practices in 2009 to identify the extent and
geospatial distribution of company reimbursed cases (Figures 1 and 2) [2]. Statewide survey
results indicated that current drugs were still effective in most practices, but that troubling hot
spots of suspected resistance were emerging. Some practices in high prevalence areas had over
50 cases per year, some reported resistance in up to 25% of dogs under their care, and 74% of
practices indicated they had seen at least one LOE case in the past year.
Faced with the uncertainty presented by apparent frequent drug failure, especially in large
breed outside dogs subjected to bites from large mosquito populations, practices in some areas
abandoned the commonly used monthly preventive drugs and began searching for alternative
preventive protocols, including use of monthly preventive drugs administered at higher doses,
long-acting injectable or topical ML drugs that maintain high continuous blood levels [8], or
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strategic use of doxycycline in combination with ML drugs [15-17]. Some of the long-acting ML
drugs have additional label claims of efficacy against other helminths in which ML is given at
elevated doses above that needed for HW prevention alone [9]. Controversies continued, as
explanations, including environmental changes, vector population shifts, and owner compliance
issues, for the growing number of LOE cases multiplied. There was a clear need to establish the
‘gold standard’ of experimental isolation and characterization of suspect cases of canine
heartworm resistance in controlled experiments.

Figure 2. Survey Question 2 - with field isolate residences noted as ‘LSU 10’ and ‘LSU 13’
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We adopted a four point ‘high index of suspicion’ criteria to enable identification and
isolation of resistant strains of D. immitis: a) clinical history of failure of efficacy and full
monetary compensation by a commercial pharmaceutical firm; b) residence in an area identified
as a ‘hotspot’ of suspected drug resistance in the 2009 statewide veterinary practitioner survey of
LOE cases [2]; c) persistence of circulating Mf seven days after an accepted microfilaricidal dose
of ML [8] and d) high frequency of a genotype marker previously reported to be correlated with
potential ML resistance, single nucleotide polymorphism at sites 11 and 618 (GG-GG) of a gene
encoding for P-glycoprotein [5].
Using these criteria for high index of suspicion, LADDL began searching for cases in
high prevalence foci of infection in Louisiana by retrospective study of positive confirmatory
antigen-based tests and Knott’s examination done on LOE cases referred to LADDL by
veterinary practitioners in order to qualify for LOE case reimbursement by pharmaceutical firms.
Two candidate dogs (LSU 10 and LSU 13) were identified in separate geographic locations
(Figure 2) that fit the four criteria and had sufficient circulating microfilariae for successful
experimental infection of laboratory dogs. Dogs were infected using L3 raised in A. aegypti from
circulating microfilariae in blood from candidate dogs [13]. For each pair, one dog was treated
with monthly subcutaneous doses of ivermectin of 12 μg/kg (twice the recommended preventive
dose for 6 months) and one dog served as an untreated control given a sham subcutaneous dose
of propylene glycol at the same monthly interval. Both treated and untreated dogs infected with
the LSU10 isolate and the LSU 13 isolate developed patent D. immitis infections by 218 DPI and
189 DPI, respectively, as evidenced by a positive occult heartworm antigen test and detection of
microfilariae by the Knott’s test. Mf counts gradually increased in number of Mf after patency in
experimentally infected dogs (Table 1), although microfilaremia in one dog (LSU 10a), initially
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found in low to moderate numbers, became sporadic with biweekly counts of 2–8 Mf per ml of
blood. It is known that up to 25% of naturally infected dogs develop ‘occult’ infections (presence
of adult heartworms without circulating Mf). This is thought to occur in some dogs due to
development of immunity-mediated removal of circulating Mf [15].
Microfilariae sent to McGill University for genomic studies showed higher genotype
frequency of the GG-GG marker [5] loci on P-glycoprotein gene from Mf population from LSU
10 and LSU 13 strain dogs compared to Mf population from LSU 11 and LSU 14 (Table 2). In a
separate follow-up study, infective larvae raised from Mf from the treated Group I dog (LSU
10a) were successfully established as a second generation isolate (LSU 10-II), confirming
heritability of resistance in the face of a monthly ivermectin challenge dose of 24 μg/kg, 4 times
the recommended preventive level for a total of 3 monthly treatments.
We propose that we have successfully isolated two strains from proven cases of
resistance that can be used to further study and characterize ML resistance by D. immitis. In a
concurrent, related study reported elsewhere, Kaminsky et al. [12] reported identification of ML
resistant strains using the same animals used for genomic and Mf motility assay studies
previously reported [3], providing independent evidence of resistance in three dogs that also
originated in LA or AR. Our study and that study are mutually confirmatory and together provide
strong evidence of the existence of ML resistant strains of D. immitis in the Lower Mississippi
Delta.
Resistance to ML and other drugs is well known for nematodes in other host species [18]
and the question may be posed as to why it took so long for resistance to emerge as a problem
with heartworm ML preventive drugs. The long, essentially annual life cycle of D. immitis [19],
a large refugia of ‘wild type’ populations in both domestic dogs and wildlife, environmental
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perturbations of mosquito vectors [20-23], and selection pressure by ‘slow-kill’ adulticide
protocols have been proposed as having a role [10,24]. Evidence of resistance to ML has been
reported for Onchocerca volvulus in long-term preventive ML chemotherapy programs in
endemic areas of Africa. It is interesting that it took a similar time frame for O. volvulus,
approximately 20 years, for documented evidence of ML resistance to emerge in the similarly
long-life cycle of this filarid species, the cause of human ‘river blindness’ [25].
The role of practicing veterinarians as the first line of defense for detection of adverse
drug effects, with FDA, has apparently been effective as a surveillance mechanism in current
heartworm control strategies. Moreover, clinical experience gained from practitioners willing to
try elective off label use of drugs and new resistance management strategies promises to lead to
new approaches to therapy that can then be proven in controlled published experiments [18,24].
For example, diethylcarbamazine was used for many years for daily use in preventing
heartworms but was then replaced by ML drugs after practitioners, kennel owners, and sporting
dog groups found that off-label use of recently released ML drugs for livestock, protected against
heartworms, intestinal helminthes and other internal parasites with very striking benefits for dogs
[26,27]. This was soon followed by controlled pharmaceutical company experimentation leading
to FDA approval and marketing in the late 1980’s of current ML drug formulations at the very
low dose levels now used for prevention of canine heartworms [26,27].
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Chapter 4. Conclusions
These experimental infection studies provide in vivo evidence of the existence of ML
drug resistance in dogs infected by D. immitis L3 from suspect field LOE cases in the Lower
Mississippi Delta. The emergence of ML resistance by D. immitis, if not controlled in the early
stages, threatens to become a widespread problem in the US that limits the effectiveness of
current preventive drug treatment methods. There is a need to develop and implement evidence
based resistance management strategies to prevent widespread selection of resistant strains where
it has been shown to exist and to suppress potential spread to other areas of the country. There is
current evidence to support the value of potential measures that may be included as part of a
resistance management strategy if confirmed by additional research and adopted by the
veterinary community. The aim is to suppress spread from dogs harboring resistant D. immitis
strains and to extend the useful life of currently available drugs: 1) Wider use of the Mf
reduction test in veterinary practices to identify suspect resistant cases [8]; 2) Development of
laboratory tests to identify resistance markers in suspect cases by microfilariae or adult worms
submitted by veterinarians; 3) Confirm that doxycycline/tetracycline therapy can be used to
suppress viability of infective larvae that develop in mosquitos from microfilariae of resistant
dogs [17] as a way to prevent infection of other dogs where strong evidence of resistance exists
(e.g. resistant dogs in the same household or neighborhood or where greatly elevated prevalence
of D. immitis in mosquitoes is likely after feeding on circulating microfilariae in a resistant dog)
[20]; 4) Use of American Heartworm Society recommended adulticide/microfilaricide treatment
protocols and avoidance of slow-kill treatment methods in which repeated treatment of infected
dogs may potentiate selection of resistance [10]; and 5) Investigate the value of alternative
preventative treatment protocols where resistant cases are found, including use of drugs that
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maintain high, sustained ML blood levels [28-30] or selective return to use of older alternative
classes of preventive drugs (e.g. daily diethylcarbamazine) [15] pending future development of
new alternative drugs.
Additionally, a time-space surveillance system may be warranted to alert the veterinary
community on the need for intervention by mapping the location of reported LOE cases and
‘high index of suspicion’ LOE cases that can be confidently attributed to true drug resistance,
such as by future genetic marker testing. Regular updates by the FDA on the status of required
LOE reports, with other records collected by pharmaceutical industry partners, may serve this
purpose. The value of an effective surveillance system may be further enhanced by development
of biology-based predictive models on the potential for spread of ML resistance based on
climate/environmental suitability determinants, and use of ecological niche models for
surveillance using geographic information systems (GIS) risk analysis methods [31-34].
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Chapter 5. Epilogue
The study, and subsequent publication described was crucial to validate the existence of
macrocyclic lactone resistant strains of Dirofilaria immitis (“it is also now indisputable that
genuinely ML-resistant heartworms are circulating, at least in the Mississippi delta region of the
USA (Pulaski et al. 2014)” (Wolstenholme et al, 2015), and the 2014 paper has now been cited in
over 45 independent publications (CrossRef: 48, Springer 96th percentile rank). Once the
presence of drug resistant heartworm infections was confirmed, the need to understand the
emergence and prevalence of these strains became apparent. The following studies are examples
of just a few of the approaches taken to further investigate these drug resistant strains.
5.1. Heartworm Preventive Drug ‘Lack of Effectiveness’ Claims Submitted to the FDA: An
Analysis of Reports, 2004 – 2015
As previously described, in 2005, Hampshire published the first peer-reviewed article on
the potential emergence of macrocyclic lactone resistance in Dirofilaria immitis based on lack of
effectiveness (LOE) claims submitted to the Center for Veterinary Medicine (CVM) within the
U.S. Food and Drug Administration (FDA).At the time, the macrocyclic lactone LOE reports
received by CVM had dramatically increased by 57% between 2000 and 2003 (reports appeared
to be decreasing between 2003 and 2004), with the majority of failures reported from heartworm
endemic states, specifically in the southeastern USA. Over the next 10 years, the veterinary
community would continue to see increasing numbers of suspect ML LOE cases, predominantly
focused in the Lower Mississippi River Alluvial Valley, and eventually a laboratory-verified
macrocyclic lactone resistant D. immitis strain would be found circulating in the area by Pulaski
and others in 2014 [35]. However, the extent of drug resistant heartworms is unknown, with a
great deal of information lacking on the prevalence and geographic range of such cases. The
objective of this study is to analyze macrocyclic lactone LOE reports submitted to CVM since
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the 2005 Hampshire paper, including the years 2004 to 2015, in order to identify possible
changes, patterns, and interactions found between and within cases.
Between the years 2004 to 2015, approximately 45,000 ML LOE claims have been
reported to CVM, with the largest numbers being reported between 2008 and 2010. Each report
is received and assigned a ‘causality score’, ranking the probability of true macrocyclic lactone
drug ineffectiveness, and scores are based primarily on timing, owner compliance, region of
incidence, and HW testing history (Figure 3). However, the assignment of a proper causality
score for each report is essential for the accuracy of these analyses, and unfortunately the
majority of reports (approx. 38,000) had not received an actual CVM causality score at the start
of this project in 2016. A comprehensive analysis is on-going, searching for epidemiologic
trends and geospatial patterns among the reports, with a focus on animal signalment,
concomitant medications, space-time relationships, and the identification of possible ‘hot spots’
around the country.
Using a data sampling approach, a statistically significant, random sample of reports was
selected for review and case series analyses, combined with reports that had previously been
reviewed.
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Figure 3. Scoring System Used by FDA to Evaluate Validity of Practitioner Reports of Lack of
Efficacy (LOE)
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Figure 4. Individual Lack of Efficacy (LOE) Reports (2004-2015) by Clinic Zip Code - pointlocated reports that scored either “0” (colored) or “6” (bullet)

5.2. Mississippi River Delta Veterinary Practitioners’ Knowledge, Attitudes, and Practices
Regarding Macrocyclic Lactone ‘Lack of Effectiveness’ Against Dirofilaria immitis
Infection, Then and Now
As illustrated in previous work [35], practitioner surveys can provide insight on complex
biological questions for limited costs, and were utilized in the present study for investigating
clinic-level perceptions and management approaches for suspected drug resistant heartworm
infections. Furthermore, as previously discussed, reports of suspected macrocyclic lactone
resistant heartworm infection reached a peak in 2007-2010, as noted in FDA LOE reports, but
these appear to be decreasing. Many have hypothesized as to the reasons for the decline in LOE
reports, although little work has been done to determine the factors which may have contributed
to the perceived variation in case numbers and/or locations. One way to examine these trends is
through veterinary practitioner surveys, which the authors have found to be useful in the past for
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investigating drug resistance in heartworms, and in 2009, the authors conducted a statewide
survey of veterinarians in Louisiana. The results of the previous survey helped to define the
extent of macrocyclic lactone resistance in the state and to identify focal ‘hot spots’ of reported
macrocyclic lactone LOEs. The objective of this study is to evaluate current trends in heartworm
disease management as reported by veterinarians in the Lower Mississippi River Alluvial Valley,
with a specific focus on changes in suspect LOE case numbers and heartworm disease prevention
and treatment protocols.
During the summer of 2016, approximately 6000 questionnaire surveys were sent out to
veterinary practitioners in the 5 Lower MS River Delta states (AR, LA, MS, MO, TN). Surveys
were mailed to every licensed veterinarian in each state, with directory information obtained
from each state’s licensing Board of Veterinary Medicine. Each practitioner received a one page
‘check-off’ questionnaire (Figure 5), with the option to complete via Qualtrics online survey
service or return via fax or pre-addressed mailer. Survey questions pertained to suspected
macrocyclic lactone LOE cases encountered in client dogs, including number of cases and
potential trends (i.e., increasing or decreasing cases). Questions also assessed each practitioner’s
currently used heartworm prevention and treatment protocols, as well as other related
information. The goal was to compare these survey results with those obtained from a similar
2009 project, with a focus on investigating possible changes or trends in HW disease
management and LOE case reporting. Survey data results were linked to a map of each state
according to the zip code of responding clinics using ArcGIS 10.5 Software, and then further
analyzed.
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Figure 5. Results For Selected Questions - Survey of veterinarians on changes in knowledge, attitude and practices from 2005-2010 in
relation to emergence of macrocyclic lactone drug resistance in a five-state area in the southeastern United States
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A total of 789 of the 5931 questionnaires distributed were returned (13.30% response rate).
Maps and detailed statistics of each survey question are available, including individual state
results and overall totals. Major highlights include:


53.37% of practitioners had seen at least one highly suspected ML LOE case within the
past 5 years; More than half of MO and TN practitioners reported not seeing a ML LOE
case within the past 5 years



31.85% reported increasing numbers of ML LOE cases since 2010, 24.28% reported
decreasing numbers, and 43.88% reported that case numbers were about the same



71.59% reported seeing less than 5 ML LOE cases within the past year



64.05% reported that they elected to treat less than 10% of their HW+ patients with a
‘slow-kill’ method (vs the recommended melarsomine protocol) within the past year:
11.34% reported treating >75% of their HW+ patients using ‘slow-kill’



Most practitioners (83.87%) administer a microfilaricidal drug, as part of their HW
treatment protocol : 76.70% report that this protocol has not changed within the past
years



93.22% administer doxycycline/minocycline as part of their HW treatment protocol:
55.39% have started including this step within the past 5 years

Based on our survey results, we were able to identify regions within the 5 states (AR, LA,
MO, MS, TN), wherein practitioners reported lower or higher numbers of suspected macrocyclic
lactone LOE cases compared to 2009. Overall, most clinics reported decreasing numbers of
suspected macrocyclic lactone LOE cases. Most clinics also reported using doxycycline or
minocycline (as part of their heartworm treatment protocols) more frequently over the past 5
years, which may help explain why several areas are seeing fewer LOE cases (when compared to
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those cases from 2005-2010). This is particularly interesting when considering that over 10% of
clinics reported treating >75% of their HW+ patients using a ‘slow-kill’ technique, and these
clinics also reported decreasing macrocyclic lactone LOE case numbers and increased use of
doxycycline/minocycline.
5.3. The Potential Use of Levamisole in a Macrocyclic Lactone Resistance Management
Strategy in Dirofilaria immitis Infections
Prior to the introduction and widespread use of macrocyclic lactone drugs in Dirofilaria
immitis infections, few options were available to prevent heartworm disease and/or eliminate
circulating microfilariae. At that time, diethylcarbamazine citrate (DEC) was the drug of choice,
although administration to microfilaremic dogs frequently resulted in severe anaphylaxis-like
reactions. Another option, levamisole hydrochloride (LEV), a synthetic imidazothiazole, showed
efficacy against D. immitis, but its use was limited. The existence of strains of D. immitis
resistant to currently available macrocyclic lactone preventive drugs has now been demonstrated
on multiple occasions, in multiple regions of the USA. Anecdotal reports in Louisiana now
indicate the number of heartworm preventive drug ‘lack of effectiveness’ (LOE) claims are
decreasing, nevertheless veterinary practitioners in some regions around the state continue to see
suspect LOE cases. Traditionally, a dog was suspected as a LOE case and thought to be infected
with resistant strains of DI when the animal developed heartworm disease, despite proper
administration of ML preventive drugs. Another approach to identify a suspect LOE case
requires the monitoring of Mf counts following the administration of macrocyclic lactones at a
dosage known to be microfilaricidal. This approach, better known as the ‘microfilariae reduction
assay’ has been shown to be useful in clinical veterinary practice situations [9].
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Case Series
History
In the summer of 2015, LSU was contacted by a veterinarian in the state regarding
suspect cases of ML resistant DI infections. The practitioner was actively involved with an
animal rescue group that specializes in the transport of shelter animals from Louisiana to various
states in the northeast USA, particularly in the New England area. Prior to transport, all adult
animals were required to be sterilized, up-to-date on vaccines, and negative for HW disease,
including both negative antigen and Mf tests. At the time, several adult dogs, including those
with adopters already arranged, were being held at the practitioner’s clinic because they
continued to have circulating Mf (detectable on blood smears), despite receiving D. immitis
adulticidal and microfilaricidal treatments. Many of these dogs were D. immitis antigen negative
and all had undergone multiple attempts to clear Mf, including the repeated administration of
high-dose IVM and topical MOX. Some of the dogs had also received a 30-day course of
doxycycline (10mg/kg PO BID), either prior to or following melarsomine injections. The
practitioner contacted LSU in order to report these suspect ML resistant cases, as well as to
inquiry about other possible Mf treatment options, in hopes of successfully relocating these dogs,
as well as avoiding the possible spread of ML resistant DI strains to regions outside the SE USA.
Plan:
LSU agreed to assist with these cases, and based on previous literature and clinical
experience, the following plan was implemented:


A thorough case history and blood would be sent to LSU from all suspect ML resistant
cases at that time, for DI antigen testing (DiroCheck®), both prior to and following the
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heat treatment of plasma samples [52], as well as quantitative Mf testing (via modified
Knott’s assay). New cases would also be enrolled, as they were identified.


After Ag and Mf status was determined, enrolled animals would receive levamisole HCl
5mg/kg PO SID x 10 days (LevaMed® Soluble Drench Power at concentration
12.4mg/ml)



Ag and Mf status of each dog would be monitored, with administration of additional
levamisole treatments as needed
Outcome:
Over 6 months, 17 dogs were enrolled in the study; circulating Mf were eliminated in 12

of the cases (based on Knott’s), while Mf were still identified in 5. However, all 5 of those
animals had very low Mf counts (<50Mf/mL), and none had Mf detectable on blood smears.
Detailed case histories from 3 representative animals are outlined in Figure 6.
Conclusions:


The use of LEV in suspect ML resistant DI infections was successful in eliminating
circulating Mf in approximately 70% of cases



Of those that still had detectable Mf; Mf numbers were highly reduced, especially when
compared to reductions observed following microfilariacidal doses of ML



The practitioner continues to use LEV as part of her ML resistant management strategy in
D. immitis infections; however she reports that LEV treatments can be challenging, as the
drug is extremely bitter and can be difficult to administer, especially to large dogs.



Since presenting this case series, other clinics outside of Louisiana have reported using
LEV in suspected ML resistant heartworm infections, with more success administering
the drug when compounded.
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Figure 6. Detailed Case Histories From 3 Representative Animals - Timeline of drug treatment with moxidectin (MOX), ivermectin
(IVO), doxycycline (Doxy), levamisole, and DI antigen (Ag- or Ag+) and/or microfilariae status
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